RNA-targeted therapeutics in cancer clinical trials: Current status and future directions

2016 ◽  
Vol 50 ◽  
pp. 35-47 ◽  
Author(s):  
Pedro Barata ◽  
Anil K. Sood ◽  
David S. Hong
Keyword(s):  
Clinical Trials ◽  
Current Status ◽  
Cancer Clinical Trials ◽  
Targeted Therapeutics ◽  
Future Directions

Abstract B022: Diversity of enrollment in prostate cancer clinical trials: Current status and future directions

2020 ◽  
Author(s):  
Emily Rencsok ◽  
Latifa Bazzi ◽  
Rana McKay ◽  
Franklin Huang ◽  
Adam Friedant ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Clinical Trials ◽  
Current Status ◽  
Cancer Clinical Trials ◽  
Future Directions

scholarly journals Diversity of Enrollment in Prostate Cancer Clinical Trials: Current Status and Future Directions

2020 ◽  
Vol 29 (7) ◽  
pp. 1374-1380 ◽  
Author(s):  
Emily M. Rencsok ◽  
Latifa A. Bazzi ◽  
Rana R. McKay ◽  
Franklin W. Huang ◽  
Adam Friedant ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Clinical Trials ◽  
Current Status ◽  
Cancer Clinical Trials ◽  
Future Directions

Randomized Phase II Designs in Cancer Clinical Trials: Current Status and Future Directions

2005 ◽  
Vol 23 (19) ◽  
pp. 4450-4457 ◽  
Author(s):  
J. Jack Lee ◽  
Lei Feng
Keyword(s):  
Clinical Trials ◽  
Phase Ii ◽  
Statistical Design ◽  
Stopping Rules ◽  
Phase Iii ◽  
Current Status ◽  
Cancer Clinical Trials ◽  
Future Directions ◽  
Randomized Phase Ii ◽  
Accrual Rate

Purpose Randomized phase II (RPh2) designs are popular in cancer clinical trials because of the smaller sample size requirements when multiple treatments are being evaluated. We reviewed the use of RPh2 designs and give comments on future directions. Design The trial design, statistical properties, conduct, data analysis, results, and reporting were examined in RPh2 trials reported from 1986 to 2002. Results A statistical design was reported in only 46% of the 266 cancer trials, and approximately half of those provided inadequate information. Most studies applied randomization to achieve patient comparability, while embedding a one-sample phase II design within each treatment arm. Seventy-five percent of the trials’ accruals were within ± 10% of their targets. The average accrual rate was 3.3 patients per month. Planned interim analyses were reported in 27% of the trials, and 56% of the trials were stopped early; 69%, 13%, 13%, and 4% of the trial discontinuations were because of lack of efficacy, efficacy, toxicity, and slow accrual, respectively. Thirty-nine trials (14%) recommended or started phase III evaluations, with four positive reports in six phase III studies identified. Conclusion There is a trend of increasing use of RPh2 designs in cancer research. Continued improvement in study design, conduct, analysis, and reporting is required to enhance the quality of RPh2 designs. The accrual rate and success rate of the trials remain low, and therefore, futility stopping rules to terminate ineffective treatment arm(s) should be implemented more frequently. More innovative, flexible RPh2 designs are needed to facilitate the development of effective cancer treatments.

Therapeutic targeting of non-coding RNAs in cancer

2017 ◽  
Vol 474 (24) ◽  
pp. 4219-4251 ◽  
Author(s):  
Ondrej Slaby ◽  
Richard Laga ◽  
Ondrej Sedlacek
Keyword(s):  
Clinical Trials ◽  
Targeted Therapeutics ◽  
Phase I Clinical Trials ◽  
Comprehensive Overview ◽  
Future Directions ◽  
New Class ◽  
Novel Treatment ◽  
Normal Expression ◽  
Non Coding Rnas

The majority of the human genome encodes RNAs that do not code for proteins. These non-coding RNAs (ncRNAs) affect normal expression of the genes, including oncogenes and tumour suppressive genes, which make them a new class of targets for drug development in cancer. Although microRNAs (miRNAs) are the most studied regulatory ncRNAs to date, and miRNA-targeted therapeutics have already reached clinical development, including the mimics of the tumour suppressive miRNAs miR-34 and miR-16, which reached phase I clinical trials for the treatment of liver cancer and mesothelioma, the importance of long non-coding RNAs (lncRNAs) is increasingly being recognised. Here, we describe obstacles and advances in the development of ncRNA therapeutics and provide the comprehensive overview of the ncRNA chemistry and delivery technologies. Furthermore, we summarise recent knowledge on the biological functions of miRNAs and their involvement in carcinogenesis, and discuss the strategies of their therapeutic manipulation in cancer. We review also the emerging insights into the role of lncRNAs and their potential as targets for novel treatment paradigms. Finally, we provide the up-to-date summary of clinical trials involving miRNAs and future directions in the development of ncRNA therapeutics.

scholarly journals Cancer Clinical Trials in Africa—An Untapped Opportunity: Recommendations From AORTIC 2019 Conference Special Interest Group in Clinical Trials

2021 ◽  
pp. 1358-1363
Author(s):  
Abiola Ibraheem ◽  
Colin Pillai ◽  
Ifeoma Okoye ◽  
J. Joshua Smith ◽  
Diane Reidy-Lagunes ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Clinical Trials ◽  
Sub Saharan Africa ◽  
Cancer Clinical Trials ◽  
Future Directions ◽  
Secondary Purpose ◽  
Health Care Burden ◽  
Sub Saharan ◽  
Cancer Disparity ◽  
And Training

Cancer is now a formidable health care burden in sub-Saharan Africa (SSA) due to lifestyle westernization and longer life expectancy. The exponential increase in cancer incidence coupled with high mortality rate is not comparable with that seen in westernized countries. To address global cancer disparity, globalization of cancer clinical trials to involve sub-Saharan Africa can serve as a platform where innovative targeted therapies can be made available to patients in the environ. In the 2019 African Organization for Research and Training in Cancer (AORTIC) conference held at Maputo, Mozambique, a group of clinical trialists spanning across multiple continents highlighted the opportunities in Africa for the conduct of cancer clinical trials. The secondary purpose of the meeting was to address the belief that Africa was incapable of conducting interventional cancer trials but showed the in-continent strengths, such as available capacities, trained local clinical trialists with clinical trial experiences, clinical trial consortia, local capabilities, mapping out logistics, ethical consideration, political will, real-time benefits of clinical trials to clinical practice, and future directions for trials.

scholarly journals Current Status and Challenges of Cancer Clinical Trials in Korea

2016 ◽  
Vol 48 (1) ◽  
pp. 20-27 ◽  
Author(s):  
Byoung Yong Shim ◽  
Se Hoon Park ◽  
Soonil Lee ◽  
Jin-Soo Kim ◽  
Kyoung Eun Lee ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Current Status ◽  
Cancer Clinical Trials
Sign in / Sign up

Export Citation Format

Share Document